ACHV.US Achieve Life Sciences Inc

Healthcare Biotechnology USA Stocks
6.78 USD
Close of Nov 13, 2026
2.62 8.64
Market cap
USD 746M
P/E
-
P/B
3.93x
ROE
-71.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ACHV.US undervalued?

Graham number

The Graham number of Achieve Life Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Achieve Life Sciences Inc fundamental analysis

No fundamental analysis for Achieve Life Sciences Inc yet.

Achieve Life Sciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Achieve Life Sciences Inc

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is he…

Full company profile